We have identified and characterized a new member of the human synuclein gene family, γ-synuclein (SNCG). This gene is composed of five exons, which encode a 127 amino acid protein that is highly homologous to α-synuclein, which is mutated in some Parkinson's disease families, and to β-synuclein. The γ-synuclein gene is localized to chromosome 10q23 and is principally expressed in the brain, particularly in the substantia nigra. We have determined its genomic sequence, and established conditions for sequence analysis of each of the exons. The γ-synuclein gene, also known as BCSG1, was recently found to be overexpressed in advanced infiltrating carcinoma of the breast. Our survey of the EST database indicated that it might also be overexpressed in an ovarian tumor.
Introduction
The synuclein gene family comprises genes that are highly conserved between species. The first synuclein gene was isolated from the electric organ of Torpedo californica (Maroteaux et al. 1988) , and soon after rat orthologs were described (Maroteaux and Scheller 1991) . In humans two members of this gene family, the α-and β-synuclein genes (SNCA and SNCB) have been characterized (Jakes et al.
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We previously identified a mutation (Ala53Thr) in the α-synuclein gene in families with the autosomal dominant form of Parkinson's disease (Polymeropoulos et al. 1997) . We hypothesized that this Ala53Thr mutation might favor the aggregation of the α-synuclein protein, ultimately resulting in cell death, and development of the disorder. Recently, another mutation (Ala30Pro) has been found in a German Parkinson's disease family (Krüger et al. 1998) . Our study of 52 Parkinson's disease patients with the sporadic form of the disease indicated that the Ala53Thr mutation is not likely to account for the majority of cases with Parkinson's disease (Polymeropoulos et al. 1997) . Evidence for locus heterogeneity in Parkinson's disease (Gasser et al. 1997; Scott et al. 1997) suggests the involvement of different genetic factors in other familial Parkinson's disease cases. It is conceivable that such genetic factors could include genes and gene products interacting with and/or similar to α-synuclein. In a search for other genes that could be mutated in patients with Parkinson's disease we have identified a third member of the synuclein gene family, which we termed γ-synuclein, that is highly expressed in the substantia nigra. In this paper we present the genomic structure of the gene and its localization to chromosome 10q23. We also found that the γ-synuclein gene sequence is almost identical to the sequence of a recently discovered gene (BCSG1) that is overexpressed in advanced infiltrating carcinoma of the breast (Ji et al. 1997) . Survey of the EST (expressed sequence tag) database revealed that the γ-synuclein gene might also be overexpressed in ovarian tumors.
Materials and methods
Database searches
Sequence homology and EST clone searches were conducted using the BLAST package of the sequence analysis program (Altschul et al. 1990 ). Searches were performed against the dbEST and GenBank databases at the following sites: dbEST http://www2.ncbi.nlm.nih.gov/dbST/dbest_query.html Genbank http://www2.ncbi.nlm.nih.gov/cgi-bin/genbank Sequencing and sequence analysis Polymerase chain reaction (PCR) products were purified through Microcon 100 (Amicon, Beverly, Mass.) and 5 ng per 100 bp was used for sequencing with the ABI Prism Dye Terminator Cycle Sequencing kit as recommended (Perkin Elmer, Foster City, Calif., USA). Sequencing reactions were purified with Centrisep spin columns (Princeton Separation, Adelphia, N.J., USA) and run on the ABI 373A sequencer. DNA and amino acid sequences were analyzed using the EditSeq, SeqMan and Megalign Programs software package (DNASTAR, Madison, Wis., USA).
Oligonucleotides and PCRs
All oligonucleotides (Table 1) were purchased from Research Genetics (Huntsville, Ala., USA). Polymerase chain reactions (20 or 100 µl) were carried out in a Perkin Elmer 9600 thermocycler using 15-50 ng of DNA as template. Three different conditions were used: (1) 94°C, 5 min; 94°C, 30 s, 55°C, 30 s, 72°C, 30 s for 30 cycles; 72°C, 10 min, and then 4°C, in 50 mM KCl, 10 mM TRIS-HCl, pH 8.3, 1.5 mM MgCl 2 , 0.01% gelatin, 200 µM dNTP (Pharmacia, Piscataway, N.J., USA), with 60 ng of each primer, and 0.3 U of AmpliTaq polymerase (Perkin Elmer); (2) same as (1) except that the annealing temperature was changed to 60°C: condition (1) was used with primer pairs γ18-γ19, γ24-26 and γ10-γ38, while condition (2) was used with primer pairs γ3-γ6, and γ25-γ37; long PCR was performed with the Expand long-template PCR system 1 (Boehringer Mannheim, Indianapolis, Ind., USA) using the following cycle: 94°C, 2 min, six cycles of 92°C, 10 s; 67°C, 30 s temperature decreased by 0.5°C at each cycle, 68°C, 6 min; six cycles of 92°C, 10 s, 64°C, 30 s, 68°C, 6 min; 23 cycles of 92°C, 10 s, 63°C, 30 s, 68°C, 6 min extension increased by 20 s at each cycle; 68°C, 7 min.
Screening of bacterial artificial chromosome (BAC) library
A BAC library purchased from Genome Systems (St. Louis, Mo., USA) was screened as described earlier (Couch et al. 1995) . BAC DNA was prepared using the Qiagen DNA extraction kit (Qiagen, Santa Clarita, Calif.).
Radiation hybrid panel and fluorescence in situ hybridization (FISH) Mapping was performed by PCR analysis of the Genebridge 4 radiation hybrid panel (Walter et al. 1994) . Statistical analysis of the data was performed using the RHMAPPER software package (D. Slonim, L. Stein, L. Kruglyak, E. Lander) at: http://www.genome.wi.mit.edu/ftp/distribution/software/rhmapper/ The FISH experiments were performed as previously described (Dutra et al. 1996) .
Northern blot analysis
Northern blots (Clontech Laboratories, Palo Alto, Calif.) were used as recommended by the manufacturer. A γ39-γ40 PCR product (Table 1) was amplified from BAC clone 174P13. A γ39-γ40 probe was generated by asymmetric PCR of 10 ng of the γ39-γ40 PCR product using primer γ40 (1 µM), in the presence of [α 32 P]dCTP (50 µCi). The probe was purified on a Sephadex G-50 column (Pharmacia) and used at 10 6 Table 1 Oligonucleotides used to determine the structure of the human γ-synuclein gene Name 5′→3′ sequence Name 5′→3′ sequence 
Results
Database search
We used DNA sequences of the α-and β-synuclein genes, (GenBank accession numbers L08850 and S69965, respectively) to search the GenBank and dbEST databases. Three homologous human sequences, M79265, AA394097 and AA293803, were identified that originated from two independent human cDNA clones, HRBAA27 and 726391 (Table  2) . These clones were homologous to both α-and β-synucleins, more precisely to the position of the gene corresponding to exons 3 and 5, respectively, of the α-synuclein sequence. We used the M79265, AA394097 and AA293803 sequences to search the same databases, and found 14 additional human DNA sequences that were all homologous to clone 726391 (Table 2) ; one clone, 858268 (sequence accession number AA633976), was homologous to the M79265, AA394097 and AA293803 sequences, indicating that clones HRBAA27 and 726391 were likely to be derived from a single new gene that was different than the α-and β-synucleins. We also identified one rat mRNA and 16 mouse cDNA sequences (Lavedan et al. in preparation) matching M79265, AA394097 and AA293803. The 5′ sequence of clone 741179 (AA402564) did not match the synuclein sequence, implying that this clone was probably chimeric (Table 2 ).
Localization
For mapping we used information derived from sequences M79265, AA394097 and AA293803. Specific human genomic markers were created by PCR. Amplicons γ1-γ2 from sequence M79265 and γ31-γ32 from sequences AA394097 and AA293803 (Fig. 1) , were used on the Genebridge 4 radiation hybrid panel (Walter et al. 1994) : both mapped to chromosome 10q23 between marker WI-5226 and marker AFM225YD12 (data not shown). In order to obtain a clone containing the entire gene, we also screened a BAC library with the same primer pairs. A clone (174P13) was isolated, and shown to contain both amplicons (data not shown). Furthermore, this BAC clone was used as a probe in FISH experiments. Two hybridization signals were seen on each metaphase examined, both on chromosome 10 (data not shown): a strong signal on 10q23 and a fainter signal in the centromeric region. We believe this is due to the presence of repeated sequences or to chimerism of the BAC clone, which would contain two independent regions of chromosome 10.
Since α-and β-synucleins have been previously mapped to 4q21-q23 (Chen et al. 1995; Shibasaki et al. 1995; Spillantini et al. 1995) and 5q35 (Spillantini et al. 1995) , respectively, these results favored the hypothesis of the existence of a new gene of the synuclein family on chromosome 10q23.
Structure of the γ-synuclein gene Additional oligonucleotides were designed (Table 1) and long PCR was performed using DNA from BAC 174P13 as a template (Fig. 1) . The size and the sequence of the amplified fragments γ1-γ35 (~1.4 kb), γ22-γ24 (~2.8 kb), γ33-γ34 (~0.42 kb) confirmed that sequences M79265, AA394097 and AA293803 were part of a single gene. The exon-intron organization (Fig. 2) was deduced from the alignment and comparison of the genomic sequence with the homologous EST sequences (Table 2) , including sequences from the α-and β-synuclein genes, and the presence of consensus intron-exon splice-junction sequences. The AUG start codon was identified based on the sequence homology with the α-and β-synuclein proteins and the presence of an excellent Kozak (1991) sequence: CCCACCATGG. This new member of the synuclein gene family, the γ-synuclein gene, spans ~5.0 kb and is composed of five exons (Figs. 1, 2) . We have developed intronic oligonucleotides and PCR conditions specifically to amplify and sequence each exon. By comparing the sequence obtained from BAC clone 174P13, four CEPH DNA controls, and the reported ESTs, we found four single nucleotide polymorphisms (SNPs) within the the γ-synuclein gene sequence ( Fig. 2) : one SNP (C→A) was observed at -19 from the AUG start codon. Another one (C→T) was detected in the 3' untranslated region, 122 bp after the UAG stop codon. One SNP changes the third nucleotide (G or C) of codon 65. More interestingly, a Comparison of human γ-synuclein, with α-and β-synucleins
The γ-synuclein gene is predicted to be transcribed as añ 0.9-kb mRNA, not including the poly(A) tail, and to encode a 127 amino acid protein (Figs. 2, 3) . Comparison of human protein sequences revealed that γ-synuclein shares 55.9 and 54.3% similarity, respectively, with the α-and β-synucleins. The most conserved regions are in the N-terminal portion of the protein, which contains repeated domains that display variations of a KTKEGV consensus sequence (Fig. 3) . The mutation that we reported in the α-synuclein gene of patients with familial Parkinson's disease, between repeat domains IV and V, changed an alanine at position 53 to a threonine (Polymeropoulos et al. 1997) . Interestingly, while β-synuclein also has an alanine at position 53, the human γ-synuclein normally has a threonine (Fig. 3) , as do the rat and mouse orthologs of the γ-synuclein protein (Lavedan et al. in preparation). Tissue expression
We studied the expression of the human γ-synuclein gene by northern analysis, using a 197-bp DNA probe (γ39-γ40) from the 3′ untranslated region that is not homologous to the α-or β-synuclein genes. The mRNA detected appeared to be ~1.0 kb, with no apparent splice variant (Fig. 4) . The γ-synuclein gene is highly expressed in the substantia nigra as well as other regions of the brain: the thalamus, the subthalamic nucleus, the hippocampus, the caudate nucleus, and the amygdala. It is also moderately expressed in the corpus callosum, the heart and the skeletal muscle, and at much lower levels in pancreas, kidney, and lung. No signal was detected in liver or placenta. In dbEST, three cDNAs originated from the brain, one from the fetal heart, one from the retina, and one from a mixture of fetal liver and spleen (Table 2) . Surprisingly, seven other clones came from the same library (NbHOT), made from an ovarian tumor (Table   2 ). Six of these seven clones are definitely independent, since their insert sizes are different and their sequences overlap (data not shown). Interestingly, when using the entire γ-synuclein sequence in a BLAST search, we found an almost perfect match with a recently released sequence of a gene called BCSG1, which is overexpressed in advanced infiltrating carcinoma of the breast (Ji et al. 1997) . Furthermore, our database search indicated that the mouse γ-synuclein ortholog is also expressed in mammary gland (Lavedan et al. in preparation) . The size of the mRNA as well as the pattern of expression of BCSG1 seem to be similar to that of γ-synuclein (Ji et al. 1997 ). BCSG1 transcripts of ~1.0 kb have been observed principally in brain but also in heart, ovary, testis, colon and spleen (Ji et al. 1997) . We found five nucleotide differences between our consensus γ-synuclein sequence and the entire 550-bp BCSG1 sequence (Genbank accession number AF010126), with no difference in the 3′ untranslated region, indicating that BCSG1 and γ-synuclein are likely to be the same gene. Only two of these differences resulted in an amino acid change: two glutamic acid residues present in γ-synuclein at positions 13 and 68 are lysines in BCSG1. These changes, E13K and E68K, were not present in the four CEPH control individuals, in BAC 174P13, or in clone HRBAA27. The glutamic acid at position 13 is indeed contained within the first repeated domain and is conserved in all known synuclein sequences (α, β, and γ) including human (Fig. 3) , rodent, bovine, canary, and electric ray. Similarly, sequences of clone 858268 and EST68G11, as well as of the four CEPH control DNAs, predict a glutamic acid at position 68 as in the rodent ortholog (Lavedan et al. in preparation) .
Discussion
We have identified and characterized a new member of the synuclein gene family, the γ-synuclein gene. This gene is highly homologous to the α-and β-synucleins. By a combination of radiation hybrid mapping and metaphase FISH, we have localized this new gene to chromosome 10q23. We have sequenced all five coding exons of the human γ-synuclein gene, and developed exon-specific PCR assays. The 1.0-kb mRNA observed on northern blots was consistent in size with that predicted from the alignment of all ESTs and PCR product sequences.
The γ-synuclein gene seems to be identical to a gene (BCSG1) overexpressed in breast cancer specimens (Ji et al. 1997) . Our survey of the EST database indicated that the human γ-synuclein gene might also be overexpressed in an ovarian tumor. Several types of genes have been shown to be involved in both breast and ovarian cancers through distinct mechanisms: mutations in tumor suppressor genes TP53 (Kupryjanczyk et al. 1993; Teneriello et al. 1993 ), BRCA1 (Miki et al. 1994) , BRCA2 (Wooster et al. 1995) , and MTS1 ); amplification and/or overexpression of proto-oncogenes such as HER-2/neu (Slamon et al. 1989 ) and AIB1 (Anzick et al. 1997) . The observation of up-regulation of BCSG1 in malignant breast epithelial cells of infiltrating carcinoma mainly of the Comedo type (Ji et al. 1997) suggests that this gene might also be a proto-oncogene. Furthermore, it is noteworthy that one of the cloned γ-synuclein cDNAs, EST75830, originated from the pineal gland, which is thought to influence the production of gonadotrophic hormones known to be implicated in breast cancer. These observations suggest that it would be important to investigate whether γ-synuclein shares a common pathway with any of the proteins involved in tumor development and/or progression of breast, ovarian, and testicular cancers, in particular its potential relationship with the estrogen pathway.
There are currently about 100 independent sequences in the GenBank databases with high homology to α-synuclein. All synuclein sequences available to date can be assigned to three distinct proteins, suggesting that the synuclein family contains only three members: α-, β-, and γ-synuclein. The high homology between γ-synuclein and α-and β-synucleins suggests a similar function that remains unknown. As a first step toward determining the role of these proteins, their patterns of expression have been examined. It has been shown that both α-and β-synucleins are concentrated in presynaptic nerve terminals (Maroteaux et al. 1988; Nakajo et al. 1993; Jakes et al. 1994) . The rat ortholog of γ-synuclein has previously been reported as being a sensory neuron protein highly expressed in dorsal root ganglia, present also in heart and spleen and at a lower level in liver and kidney (Akopian and Wood 1995) . We have shown that the human γ-synuclein gene is highly expressed in various areas of the brain, moderately in the corpus callosum, the heart, and skeletal muscle, and at a much lower level in pancreas, kidney, and lung. This result is consistent with the data reported for BCSG1, which also appears to be expressed at low levels in ovary, testis and colon (Ji et al. 1997) . The high level of expression of γ-synuclein in the substantia nigra, the main region of neuronal degeneration in the brains of patients with Parkinson's disease, and its high homology to α-synuclein, which is mutated in some familial cases of Parkinson's disease (Polymeropoulos et al. 1997 ), points to γ-synuclein as a new candidate gene for Parkinson's disease.
Knowing the localization, sequence, and structure of the γ-synuclein gene, including oligonucleotide sequences and conditions for PCR amplification of each exon, will facilitate the search for mutations in this gene and allow examination of its involvement in Parkinson's disease and in other neurodegenerative disorders, as well as in the development and/or progression of breast and ovarian tumors.
